ClinicalTrials.gg
CompletedNCT02574455ASCENTUpdated Jun 15, 2022Results posted

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

A Phase 3 interventional study of Sacituzumab govitecan and Eribulin in Breast Cancer, sponsored by Gilead Sciences. Completed at 230 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing sacituzumab govitecan in Breast Neoplasms — 16 open to participants now, 24 under way, 4 of them phase 3. sacituzumab govitecan · Breast Neoplasms.

Enrollment
5th of 27
529 · median 75
Started
2017
the only one that year
Phase 3
6 of 27
1 open now
Registered
2nd of 27
by date
Lead sponsor
5 of 27
Gilead Sciences

Among the 27 studies testing sacituzumab govitecan in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 27 studies testing sacituzumab govitecan in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sacituzumab govitecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free survival (PFS) in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) previously treated with at least two systemic chemotherapy regimens for unresectable, locally advanced or metastatic disease, and without brain metastasis at baseline.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed TNBC based on the most recent analyzed or other pathology specimen. Triple negative is defined as \<1% expression for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 () by in-situ hybridization.
  • to or relapsed after at least two prior standard therapeutic regimens for advanced/ TNBC.
  • Prior exposure to a taxane in localized or advanced/metastatic setting.
  • Eligible for one of the chemotherapy options listed as TPC (eribulin, capecitabine, gemcitabine, or vinorelbine) as per investigator assessment.
  • (ECOG) performance score of 0 or 1.
  • by computed tomography (CT) or magnetic resonance imaging (MRI) as per version 1.1 (RECIST 1.1). Bone-only disease is not permitted.
  • At least 2 weeks beyond prior anti-cancer treatment (chemotherapy, endocrine therapy, radiotherapy, and/or major surgery), and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).
  • At least 2 weeks beyond high dose systemic (however, low dose corticosteroids \< 20 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).
  • Adequate hematology without ongoing transfusional support ( > 9 g/dL, (ANC) > 1,500 per mm\^3, > 100,000 per mm\^3).
  • Adequate renal and hepatic function ( [CrCL] > 60 mL/min, ≤ 1.5 institutional [IULN], [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin ≥3 g/dL).
  • Recovered from all toxicities to Grade 1 or less by National Cancer Institute (NCI CTCAE) v4.03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Participants with Grade 2 neuropathy are eligible but may not receive vinorelbine as TPC.
  • Participants with treated, non-progressive , off high-dose steroids (>20 mg prednisone or equivalent) for at least 4 weeks can be enrolled in the trial.

Key Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Women of or fertile men unwilling to use effective during study and up to three months after treatment discontinuation in women of child-bearing potential and six months in males post last study drug.
  • Participants with Gilbert's disease.
  • Participants with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while participants with other prior must have had at least a 3-year disease-free interval.
  • Participants known to be human immunodeficiency () positive, positive, or positive.
  • Infection requiring antibiotic use within one week of randomization.
  • Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan

    Participants will receive sacituzumab govitecan on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable adverse events (AEs).

    Drug: Sacituzumab govitecan

  • Active comparator
    Treatment of Physician's Choice (TPC)

    Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.

    Drug: Eribulin · Drug: Capecitabine · Drug: Gemcitabine · Drug: Vinorelbine

Interventions

  • 10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.

    Also known as: IMMU-132, Trodelvy®

  • Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).

    Also known as: Halaven

  • 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.

    Also known as: Xeloda

  • 800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.

    Also known as: Gemzar

  • 25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.

    Also known as: Navelbine

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population

    PFS was defined as the time from randomization until objective tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death, whichever came first. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (greater than or equal to \[≥\] 20%) in the sum of the target lesions or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

    Time frame: From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

Secondary outcomes

  1. Progression-Free Survival (PFS) by IRC Assessment in the ITT Population

    PFS was defined as the time from randomization until objective tumor progression by RECIST v1.1 or death, whichever came first. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

    Time frame: From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  2. Overall Survival (OS) in BM-ve Population

    Overall survival (OS) was defined as the time from the randomization to death from any cause. OS was estimated using Kaplan-Meier estimate.

    Time frame: From the randomization to death from any cause (maximum follow-up duration: 30.8 months)

  3. Overall Survival (OS) in ITT Population

    Overall survival (OS) was defined as the time from the randomization to death from any cause. OS was estimated using Kaplan-Meier estimate.

    Time frame: From the randomization to death from any cause (maximum follow-up duration: 30.8 months)

  4. Objective Response Rate (ORR) by IRC and Investigator Assessment in BM-ve Population

    ORR was defined as the percentage of participants who had the overall best response as either a confirmed complete response (CR) or partial response (PR) relative to the size of population under evaluation. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; and no new lesions.

    Time frame: From randomization to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  5. Time to Objective Response by the Investigator Assessment in BM-ve Population

    Time to response was defined as the time from randomization to the first recorded objective response (ie, CR or PR). CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions.

    Time frame: From randomization to the first recorded objective response (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  6. Time to Objective Response by the IRC Assessment in BM-ve Population

    Time to response was defined as the time from randomization to the first recorded objective response (ie, CR or PR). CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions.

    Time frame: From randomization to the first recorded objective response (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  7. Duration of Response (DOR) by IRC and Investigator Assessment in BM-ve Population

    DOR was defined as the number of days between the first date showing a documented response of CR or PR and the date of progression or death. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions.

    Time frame: From the first date of documented response of CR or PR to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  8. Time to Progression (TTP) by Investigator Assessment in BM-ve Population

    Time to Progression (TTP) was defined as the time from the date of randomization to the date of the first evidence of disease progression as assessed using RECIST 1.1 criteria. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. Participants without progression were censored.

    Time frame: From randomization until disease progression (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  9. Time to Progression (TTP) by IRC Assessment in BM-ve Population

    Time to Progression (TTP) was defined as the time from the date of randomization to the date of the first evidence of disease progression as assessed using RECIST 1.1 criteria. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. Participants without progression were censored.

    Time frame: From randomization until disease progression (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  10. Clinical Benefit Rate (CBR) by IRC and Investigator Assessment in BM-ve Population

    CBR was defined as the percentage of participants with best response as either CR, PR, or stable disease (SD) with a duration of ≥6 months. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started; and Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits. PD: ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since treatment started or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: From randomization to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)

  11. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation of Study Drug

    Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above

    Time frame: First dose date up to last follow-up (maximum up to 30.8 months)

  12. Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score

    The EORTC QLQ-C30 is a questionnaire to assess quality of life (QoL), it is composed of 30 questions (items) resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom and single-item scales indicate a better quality of life; a negative change from baseline indicates improvement.

    Time frame: Baseline; End of Treatment (EOT) (up to 29.6 months)

  13. Percentage of Participants Experiencing the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline

    Blood samples were collected for hematology, serum chemistry and the laboratory abnormalities were assessed. The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.

    Time frame: First dose date up to last follow-up (maximum up to 30.8 months)

07

Results

Posted Apr 30, 2021

Participant flow

Participants were enrolled at study sites in Belgium, Canada, France, Germany, Spain, the United Kingdom, and the United States. The first participant was screened on 07 November 2017. The last study visit occurred on 08 December 2020.

Participant flow — Overall Study
MilestoneSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Started267262
Enrolled and treated258224
Completed00
Not completed267262
Withdrew: Death197210
Withdrew: Withdrawal of consent1128
Withdrew: Lost to follow-up44
Withdrew: Sponsor's decision5520

Outcome measures

PrimaryProgression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population

PFS was defined as the time from randomization until objective tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death, whichever came first. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (greater than or equal to \[≥\] 20%) in the sum of the target lesions or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

Time frame:
From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Median · months
Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population5.6 (4.3 to 6.3)1.7 (1.5 to 2.6)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies, presence of known brain metastases at study entry, and region.) · Hazard ratio (hr): 0.387 · 95% CI 0.305 to 0.492
SecondaryProgression-Free Survival (PFS) by IRC Assessment in the ITT Population

PFS was defined as the time from randomization until objective tumor progression by RECIST v1.1 or death, whichever came first. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.

Time frame:
From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Median · months
Progression-Free Survival (PFS) by IRC Assessment in the ITT Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Progression-Free Survival (PFS) by IRC Assessment in the ITT Population4.8 (4.1 to 5.8)1.7 (1.5 to 2.5)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies, presence of known brain metastases at study entry, and region.) · Hazard ratio (hr): 0.413 · 95% CI 0.330 to 0.517
SecondaryOverall Survival (OS) in BM-ve Population

Overall survival (OS) was defined as the time from the randomization to death from any cause. OS was estimated using Kaplan-Meier estimate.

Time frame:
From the randomization to death from any cause (maximum follow-up duration: 30.8 months)
Reported as:
Median · months
Overall Survival (OS) in BM-ve Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Overall Survival (OS) in BM-ve Population12.1 (10.7 to 14.0)6.7 (5.8 to 7.7)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies and region.) · Hazard ratio (hr): 0.481 · 95% CI 0.390 to 0.592
SecondaryOverall Survival (OS) in ITT Population

Overall survival (OS) was defined as the time from the randomization to death from any cause. OS was estimated using Kaplan-Meier estimate.

Time frame:
From the randomization to death from any cause (maximum follow-up duration: 30.8 months)
Reported as:
Median · months
Overall Survival (OS) in ITT Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Overall Survival (OS) in ITT Population11.8 (10.5 to 13.8)6.9 (5.9 to 7.7)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies and region.) · Hazard ratio (hr): 0.514 · 95% CI 0.422 to 0.625
SecondaryObjective Response Rate (ORR) by IRC and Investigator Assessment in BM-ve Population

ORR was defined as the percentage of participants who had the overall best response as either a confirmed complete response (CR) or partial response (PR) relative to the size of population under evaluation. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; and no new lesions.

Time frame:
From randomization to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by IRC and Investigator Assessment in BM-ve Population
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
ORR by IRC Assessment34.9 (28.8 to 41.4)4.7 (2.4 to 8.3)
ORR by Investigator Assessment33.2 (27.2 to 39.6)6.4 (3.6 to 10.4)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 10.859 · 95% CI 5.590 to 21.095
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 7.363 · 95% CI 4.063 to 13.341
SecondaryTime to Objective Response by the Investigator Assessment in BM-ve Population

Time to response was defined as the time from randomization to the first recorded objective response (ie, CR or PR). CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions.

Time frame:
From randomization to the first recorded objective response (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Mean · months
Time to Objective Response by the Investigator Assessment in BM-ve Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Time to Objective Response by the Investigator Assessment in BM-ve Population2.14 ± 1.3222.72 ± 2.933
SecondaryTime to Objective Response by the IRC Assessment in BM-ve Population

Time to response was defined as the time from randomization to the first recorded objective response (ie, CR or PR). CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions.

Time frame:
From randomization to the first recorded objective response (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Mean · months
Time to Objective Response by the IRC Assessment in BM-ve Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Time to Objective Response by the IRC Assessment in BM-ve Population2.67 ± 1.9131.86 ± 0.919
SecondaryDuration of Response (DOR) by IRC and Investigator Assessment in BM-ve Population

DOR was defined as the number of days between the first date showing a documented response of CR or PR and the date of progression or death. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions.

Time frame:
From the first date of documented response of CR or PR to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Median · months
Duration of Response (DOR) by IRC and Investigator Assessment in BM-ve Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
IRC Assessment6.3 (5.5 to 7.9)3.6 (2.8 to NA)
Investigator Assessment6.9 (5.6 to 7.9)3.0 (2.8 to 4.3)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = 0.0683 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies, and region.) · Hazard ratio (hr): 0.407 · 95% CI 0.150 to 1.107
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies, and region.) · Hazard ratio (hr): 0.212 · 95% CI 0.103 to 0.435
SecondaryTime to Progression (TTP) by Investigator Assessment in BM-ve Population

Time to Progression (TTP) was defined as the time from the date of randomization to the date of the first evidence of disease progression as assessed using RECIST 1.1 criteria. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. Participants without progression were censored.

Time frame:
From randomization until disease progression (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Median · months
Time to Progression (TTP) by Investigator Assessment in BM-ve Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Time to Progression (TTP) by Investigator Assessment in BM-ve Population5.7 (5.2 to 6.9)1.8 (1.5 to 2.6)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies and region.) · Hazard ratio (hr): 0.317 · 95% CI 0.248 to 0.404
SecondaryTime to Progression (TTP) by IRC Assessment in BM-ve Population

Time to Progression (TTP) was defined as the time from the date of randomization to the date of the first evidence of disease progression as assessed using RECIST 1.1 criteria. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. Participants without progression were censored.

Time frame:
From randomization until disease progression (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Median · months
Time to Progression (TTP) by IRC Assessment in BM-ve Population
monthsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Time to Progression (TTP) by IRC Assessment in BM-ve Population5.8 (4.8 to 6.9)2.1 (1.5 to 2.7)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Log Rank · p = <0.0001 (Stratified log-rank test and stratified Cox regression adjusted for stratification factors: number of prior chemotherapies and region.) · Hazard ratio (hr): 0.406 · 95% CI 0.315 to 0.525
SecondaryClinical Benefit Rate (CBR) by IRC and Investigator Assessment in BM-ve Population

CBR was defined as the percentage of participants with best response as either CR, PR, or stable disease (SD) with a duration of ≥6 months. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started; and Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits. PD: ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since treatment started or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
From randomization to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) by IRC and Investigator Assessment in BM-ve Population
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
IRC Assessment44.7 (38.2 to 51.3)8.6 (5.3 to 12.9)
Investigator Assessment45.5 (39.0 to 52.1)10.3 (6.7 to 14.9)
Statistical analysis
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 8.543 · 95% CI 5.055 to 14.437
  • Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 7.492 · 95% CI 4.540 to 12.364
SecondaryPercentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation of Study Drug

Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above

Time frame:
First dose date up to last follow-up (maximum up to 30.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation of Study Drug
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Any TEAEs99.697.8
SAEs26.728.6
TEAEs Leading to Discontinuation of Study Drug4.75.4
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score

The EORTC QLQ-C30 is a questionnaire to assess quality of life (QoL), it is composed of 30 questions (items) resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom and single-item scales indicate a better quality of life; a negative change from baseline indicates improvement.

Time frame:
Baseline; End of Treatment (EOT) (up to 29.6 months)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score
score on a scaleSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Global Health Status/QoL: Baseline61.9 ± 21.3156.4 ± 22.21
Global Health Status/QoL: Change From Baseline at EOT-5.8 ± 22.71-9.4 ± 20.46
Physical Functioning: Baseline73.2 ± 21.6971.2 ± 21.24
Physical Functioning: Change From Baseline at EOT-4.6 ± 21.07-13.5 ± 20.54
Role Functioning: Baseline68.1 ± 30.3565.1 ± 30.31
Role Functioning: Change From Baseline at EOT-8.4 ± 32.87-18.8 ± 29.83
Emotional Functioning: Baseline71.9 ± 22.3368.9 ± 23.87
Emotional Functioning: Change From Baseline at EOT-3.8 ± 25.02-3.5 ± 22.16
Cognitive Functioning: Baseline81.7 ± 21.0879.5 ± 23.91
Cognitive Functioning: Change From Baseline at EOT-7.5 ± 22.81-6.1 ± 22.92
Social Functioning: Baseline69.1 ± 29.9669.6 ± 26.88
Social Functioning: Change From Baseline at EOT-5.9 ± 27.52-10.3 ± 29.60
Fatigue: Baseline39.4 ± 25.7242.1 ± 25.99
Fatigue: Change From Baseline at EOT5.1 ± 25.9314.0 ± 23.05
Nausea and Vomiting: Baseline8.3 ± 16.3610.3 ± 18.26
Nausea and Vomiting: Change From Baseline at EOT5.2 ± 23.937.3 ± 23.33
Pain: Baseline37.9 ± 30.5442.5 ± 30.38
Pain: Change From Baseline at EOT2.8 ± 27.846.8 ± 30.33
Dyspnoea: Baseline25.4 ± 30.3625.0 ± 29.09
Dyspnoea: Change From Baseline at EOT0.7 ± 30.915.9 ± 28.95
Insomnia: Baseline33.2 ± 30.9535.6 ± 31.42
Insomnia: Change From Baseline at EOT4.4 ± 34.67-4.3 ± 32.24
Appetite Loss: Baseline20.8 ± 27.3425.8 ± 28.68
Appetite Loss: Change From Baseline at EOT3.1 ± 31.7810.0 ± 30.32
Constipation: Baseline17.7 ± 27.1819.0 ± 26.56
Constipation: Change From Baseline at EOT3.3 ± 28.927.0 ± 31.27
Diarrhoea: Baseline7.2 ± 17.736.5 ± 15.69
Diarrhoea: Change From Baseline at EOT11.4 ± 28.563.6 ± 22.46
Financial Difficulties: Baseline27.6 ± 34.3922.4 ± 30.91
Financial Difficulties: Change From Baseline at EOT0.4 ± 24.091.1 ± 23.54
SecondaryPercentage of Participants Experiencing the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline

Blood samples were collected for hematology, serum chemistry and the laboratory abnormalities were assessed. The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.

Time frame:
First dose date up to last follow-up (maximum up to 30.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline
percentage of participantsSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Anemia8.95.4
Lymphocyte Count Decreased33.325.0
Neutrophil Count Decreased48.835.3
Platelet Count Decreased1.22.7
White Blood Cell Decreased41.125.4
Alanine Aminotransferase Increased1.22.2
Alkaline Phosphatase Increased3.13.6
Aspartate Aminotransferase Increased3.52.2
Blood Bilirubin Increased1.92.7
Creatinine Increased0.40
Hypercalcemia00.4
Hyperglycemia3.13.1
Hyperkalemia0.80
Hypermagnesemia0.40.4
Hypernatremia00
Hypoalbumenemia0.81.3
Hypocalcemia1.61.3
Hypoglycemia0.40
Hypokalemia4.30.9
Hypomagnesemia0.80
Hyponatremia3.93.6
Hypophosphatemia8.13.6

Adverse events

Collected over Adverse Events: First dose date up to last follow-up (maximum up to 30.8 months); All-Cause Mortality: From randomization up to 30.8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacituzumab Govitecan201/267 (75.3%)69/258 (26.7%)256/258 (99.2%)
Treatment of Physician's Choice (TPC)222/262 (84.7%)64/224 (28.6%)213/224 (95.1%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventSacituzumab GovitecanTreatment of Physician's Choice (TPC)
Febrile neutropeniaBlood and lymphatic system disorders13/2584/224
DiarrhoeaGastrointestinal disorders9/2580/224
DyspnoeaRespiratory, thoracic and mediastinal disorders2/2587/224
PneumoniaInfections and infestations7/2584/224
Pleural effusionRespiratory, thoracic and mediastinal disorders2/2586/224
PyrexiaGeneral disorders3/2585/224
NeutropeniaBlood and lymphatic system disorders5/2581/224
SepsisInfections and infestations2/2584/224
Back painMusculoskeletal and connective tissue disorders2/2584/224
Abdominal painGastrointestinal disorders3/2583/224
Most frequent other events
Showing 10 of 62
Most frequent other events
EventSacituzumab GovitecanTreatment of Physician's Choice (TPC)
DiarrhoeaGastrointestinal disorders168/25838/224
NauseaGastrointestinal disorders160/25868/224
FatigueGeneral disorders133/25889/224
AlopeciaSkin and subcutaneous tissue disorders121/25836/224
NeutropeniaBlood and lymphatic system disorders108/25856/224
AnaemiaBlood and lymphatic system disorders102/25861/224
ConstipationGastrointestinal disorders96/25852/224
VomitingGastrointestinal disorders85/25836/224
Neutrophil count decreasedInvestigations71/25845/224
Decreased appetiteMetabolism and nutrition disorders71/25846/224

Baseline characteristics

The Intent-to-Treat (ITT) Population included all randomized participants.

Age, Continuous
Age, Continuous(years)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total
Mean54.0 ± 11.3454.0 ± 11.6954.0 ± 11.50
Sex: Female, Male
Sex: Female, Male(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total
Female265262527
Male202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total
Hispanic or Latino202545
Not Hispanic or Latino234226460
Unknown or Not Reported131124
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total
Race — Asian13922
Race — Black283462
Race — White215203418
Race — Other111627
Region of Enrollment
Region of Enrollment(participants)Sacituzumab GovitecanTreatment of Physician's Choice (TPC)Total
Belgium202545
Canada325
France332962
Germany022
Spain322658
United Kingdom7815
United States172170342
08

Study locations

230 sites
  • Southern Cancer Center, 29653 Anchor Cross Blvd
    Daphne, Alabama 36526, United States
  • Souther Cancer Center, 3719 Dauphin St., 5 Floor
    Mobile, Alabama 36608, United States
  • Southern Cancer Center, 3 Mobile Infirmary Circle
    Mobile, Alabama 36608, United States
  • Southern Cancer Center, 6701 Airport Blvd., Bldg B, Terace Level
    Mobile, Alabama 36608, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Mayo Clinic Hospital
    Scottsdale, Arizona 85259, United States
  • UCLA Jonsson Comprehensive Cancer Center, 1411 S. Garfield Ave Suite 200
    Alhambra, California 91801, United States
  • UCLA Jonsson Comprehensive Cancer Center, 201. S. Buena Vista St Suite 200
    Burbank, California 91505, United States
  • UCLA Jonsson Comprehensive Cancer Center
    Laguna Hills, California 92653, United States
  • UCLA Jonsson Comprehensive Cancer Center, 200 UCLA Medical Plaza
    Los Angeles, California 90095, United States
  • UCLA Jonsson Comprehensive Cancer Center, 625 South Fair Oaks Avenue Suite 320
    Pasadena, California 91105, United States
  • University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, 1600 Divisadero Street
    San Francisco, California 94115, United States
  • UCLA Jonsson Comprehensive Cancer Center, 2020 Santa Monica Boulevard
    Santa Monica, California 94115, United States
  • Rocky Mountain Cancer Centers, 1700 South Potomac Street
    Aurora, Colorado 80012-5405, United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion, 1665 Aurora Court
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Centers, 4715 Arapahoe Ave
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers, 2312 N. Nevada Avenue, Suite 400
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers, 1800 Williams St.
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers, 4700 E. Hale Parkway, Suite 400
    Denver, Colorado 80220, United States
  • Rocky Mountain Cancer Centers, 499 E Hampden Ave Suite 450
    Englewood, Colorado 80113, United States
  • Rocky Mountain Cancer Centers, 11750 West 2nd Place, Suite 1-100
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers, 22 West Dry Creek Circle
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer Centers, 10103 Ridge Gate Parkway, Suite G-01
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers, 2030 W Mountain View Avenue, Ste. 210
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers, 9397 Crown Crest Blvd., Suite 421
    Parker, Colorado 80138, United States
  • Rocky Mountain Cancer Centers, 3676 Parker Blvd., Suite 350
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers, 8820 Huron Street
    Thornton, Colorado 80260, United States
  • Yale School Of Medicine
    New Haven, Connecticut 06510-3206, United States
  • Norwalk Hospital, 34 Maple Street
    Norwalk, Connecticut 06856, United States
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists & Research Institute, 601 E. Altamonte Drive
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialist
    Bonita Springs, Florida 34135, United States
  • Florida Cancer Specialists
    Bradenton, Florida 34209, United States
  • Florida Cancer Specialists & Research Institute, 403 S. King Ave
    Brandon, Florida 33511, United States
  • Florida Cancer Specialists
    Cape Coral, Florida 33914, United States
  • Florida Cancer Specialists & Research Institute, 3280 McMullen Booth road
    Clearwater, Florida 33761, United States
  • Sylvester Comprehensive Cancer Center
    Coral Gables, Florida 33146, United States
  • Florida Cancer Specialists & Research Institute, 224 Memorial medical Parway
    Daytona Beach, Florida 32117, United States
  • Sylvester Comprehensive Cancer Center
    Deerfield Beach, Florida 33442, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialists & Research Institute, 6420 W Newberry Road Est Wing
    Gainesville, Florida 32605, United States
  • Florida Cancer Specialists & Research Institute, 100 Highland Avenue
    Largo, Florida 33770, United States
  • Florida Cancer Specialists & Research Institute, 521 N. Lecanto Highway
    Lecanto, Florida 34461, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Baptist Health Medical Group Oncology, LLC
    Miami, Florida 33176, United States
  • Florida Cancer Specialists
    Naples, Florida 34102, United States
  • Florida Cancer Specialists & Research Institute, 8763 River Crossing Blvd
    New Port Richey, Florida 34655, United States
  • Florida Cancer Specialists & Research Institute, 1630 SE 18th ST
    Ocala, Florida 34471, United States
  • Florida Cancer Specialists & Research Institute, 765 Image Way
    Orange City, Florida 32763, United States
  • Orlando Regional Medical Center
    Orlando, Florida 32806-2008, United States
  • Florida Cancer Specialists & Research Institute, 70 W Gore Street
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists & Research Institute - 325 Clyde Morris
    Ormond Beach, Florida 32774, United States
  • Sylvester Comprehensive Cancer Center
    Plantation, Florida 33324, United States
  • Florida Cancer Specialists
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists & Research Institute, 1201 Fifth Avenue North
    Saint Petersburg, Florida 33705-1449, United States
  • Florida Cancer Specialists & Research Institute, 560 Jackson St
    Saint Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists & Research Institute, 7154 Medical Center Drive
    Spring Hill, Florida 34608, United States
  • Florida Cancer Specialists & Research Institute, 3402 W Dr. Martin Luther King Jr Boulevard
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists & Research Institute, 4100 Waterman Way
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists & Research Institute, 1400 US highway 441 N
    The Villages, Florida 32159, United States
  • Florida Cancer Specialists
    Venice, Florida 34285, United States
  • Florida Cancer Specialists
    Venice, Florida 34292, United States
  • Florida Cancer Specialists & Research Institute - 3730 7th Terrace
    Vero Beach, Florida 32960, United States
  • Florida Cancer Specialists & Research Institute, 1037 State Road 7 Bldg B
    Wellington, Florida 98374, United States
  • Florida Cancer Specialists & Research Institute1309 N Flagler Dr
    West Palm Beach, Florida 33401-3406, United States
  • Florida Cancer Specialists & Research Institute, 2100 Glenwood Drive
    Winter Park, Florida 32792, United States
  • Atlanta Cancer Center - Alpharetta
    Alpharetta, Georgia 30005, United States
  • University Cancer & Blood Center, 3320 Old Jefferson Rd
    Athens, Georgia 30607, United States
  • GCS/Annex
    Atlanta, Georgia 30341, United States
  • Atlanta Cancer Care - Atlanta
    Atlanta, Georgia 30342, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • GCS/Canton
    Canton, Georgia 30114, United States
  • Atlanta Cancer Care - Conyers
    Conyers, Georgia 30094, United States
  • Atlanta Cancer Care - Cumming
    Cumming, Georgia 30041, United States
  • Atlanta Cancer Care - Decatur
    Decatur, Georgia 30033, United States
  • GCS/Stemmer
    Decatur, Georgia 30033, United States
  • Atlanta Cancer Care - Stockbridge
    Jonesboro, Georgia 30236, United States
  • GCS/Macon
    Macon, Georgia 31217, United States
  • GCS/Kennestone
    Marietta, Georgia 30060, United States
  • GCS/Northside
    Sandy Springs, Georgia 30342, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • University of Chicago Medical Center 5841 S. Maryland Ave
    Chicago, Illinois 60637, United States
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital 1900 Silver Cross Blvd
    New Lenox, Illinois 60451, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714-5905, United States
  • Orland Park - UCMC Center for Advanced Care 14290 South LaGrange Rd
    Orland Park, Illinois 60462, United States
  • MidAmerica Division Inc. c/o Menorah Medical Center
    Overland Park, Kansas 66209, United States
  • University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion
    Westwood, Kansas 66205-2005, United States
  • Maryland Oncology Hematology
    Bethesda, Maryland 20817, United States
  • Maryland Oncology Hematology
    Brandywine, Maryland 20613, United States
  • Maryland Oncology Hematology
    Clinton, Maryland 20735, United States
  • Maryland Oncology Hematology
    Columbia, Maryland 21044, United States
  • Maryland Oncology Hematology
    Rockville, Maryland 20850, United States
  • Maryland Oncology Hematology
    Silver Spring, Maryland 20902, United States
  • Maryland Oncology Hematology
    Silver Spring, Maryland 20904, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02114-2621, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center (BIDMC)
    Boston, Massachusetts 02215-5400, United States
  • Mass General - North Shore Cancer Center ( NSCC )
    Danvers, Massachusetts 01923, United States
  • Mercy Hospital
    Coon Rapids, Minnesota 55433, United States

Showing the first 100 of 230 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. PubMed 30786188 ↗
  • Huvitz SA, Tolaney SM, Punie K, et al. 2020 SABCS GS3-06. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium; December 8-11, 2020; San Antonio, TX.
  • Dieras V, Weaver R, Tolaney SM, et al. 2020 SABCS PD13-07. Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium; December 8-11, 2020; San Antonio, TX.
  • Rugo HS, Tolaney SM, Loirat D, et al. 2020 SABCS PS11-09. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium; December 8-11, 2020; San Antonio, TX.
  • Bardia A, Tolaney SM, Loirat D, et al. ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325
  • Bardia A, Rugo RS, Horne H, et al. A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2018;78 (4 Supplement): OT2-07-05
  • O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortes J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. PubMed 35545724 ↗
  • Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021 Oct 1;17(30):3911-3924. doi: 10.2217/fon-2021-0868. Epub 2021 Sep 1. PubMed 34467774 ↗
  • Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortes J, O'Shaughnessy J, Dieras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PubMed 33882206 ↗
  • McCann KE, Hurvitz SA. Innovations in targeted therapies for triple negative breast cancer. Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):34-47. doi: 10.1097/GCO.0000000000000671. PubMed 33093337 ↗
  • Seligson JM, Patron AM, Berger MJ, Harvey RD, Seligson ND. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17. PubMed 33070624 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2020, 28 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 12, 2015
StartActual
Nov 7, 2017
Primary completionActual
Mar 30, 2020
CompletionActual
Dec 8, 2020
Results first posted
Apr 30, 2021
Last update
Jun 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02574455
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 12, 2015
Start date
Nov 7, 2017
Primary completion
Mar 30, 2020
Completion
Dec 8, 2020
Results posted
Apr 30, 2021
Last update
Jun 15, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion